Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3831283 Target Snapshot

NEDD8 activating enzyme · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
265Compounds
61Assays
1Approved Drugs
402.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

NEDD8 activating enzyme shows late clinical disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q8TBC4. Start with acute myeloid leukemia, then reuse UniProt Q8TBC4 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acute myeloid leukemia, then reuse UniProt Q8TBC4 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
acute myeloid leukemia

NEDD8 activating enzyme shows late clinical disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with acute myeloid leukemia because it currently carries late clinical support. Linked drugs include PEVONEDISTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NEDD8 activating enzyme as ChEMBL target CHEMBL3831283, mapped to UniProt Q8TBC4. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NEDD8 activating enzyme
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3831283
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q8TBC4
NEDD8-activating enzyme E1 catalytic subunit
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether NEDD8 activating enzyme is the right protein anchor across sources, using UniProt Q8TBC4 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acute myeloid leukemia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameNEDD8 activating enzyme
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtQ8TBC4
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNEDD8-activating enzyme E1 catalytic subunit
UniProt AccessionQ8TBC4
Component TypeProtein
Sequence Length463 aa

NEDD8-activating enzyme E1 catalytic subunit

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as NEDD8 activating enzyme, mapped to UniProt Q8TBC4. ChEMBL maps the protein component as NEDD8-activating enzyme E1 catalytic subunit. Sequence length is 463 aa.

Mapped IDQ8TBC4
Review nameNEDD8 activating enzyme
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

NEDD8 activating enzyme shows late clinical disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugPEVONEDISTAT
Clinical signal Phase II
cholangiocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPEVONEDISTAT
Clinical signal Phase II
chronic myelomonocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugPEVONEDISTAT
Clinical signal Phase II
hepatocellular carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPEVONEDISTAT
Clinical signal Phase II
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugPEVONEDISTAT
Clinical signal Phase II
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPEVONEDISTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with acute myeloid leukemia because it currently carries late clinical support. Linked drugs include PEVONEDISTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacute myeloid leukemia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
2
Phase III
Assay Mix

Activity Type Distribution

IC50398.0
EC503.0
KD1.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5170838 10.7 IC50 0.02 Preclinical
CHEMBL5182746 9.68 IC50 0.21 Preclinical
CHEMBL1231160 9.59 IC50 0.26 Clinical
CHEMBL5177755 9.26 IC50 0.55 Preclinical
CHEMBL5206652 9.24 IC50 0.57 Preclinical
CHEMBL4569826 9.22 IC50 0.6 Preclinical
CHEMBL4582044 9.05 IC50 0.9 Preclinical
CHEMBL5175806 9.02 IC50 0.955 Preclinical
CHEMBL5181979 9.0 IC50 1.0 Preclinical
CHEMBL5173723 8.65 IC50 2.23 Preclinical
Distribution

pChEMBL Value Distribution

1
5.0
3
5.5
89
6.0
26
6.5
9
7.0
16
7.5
15
8.0
2
8.5
6
9.0
2
9.5
pChEMBL
Assay Landscape

Assay Landscape

61
Total Assays
165
Tested Compounds
1
Assay Types
Binding — 61 assays, 165 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 46 37 6.4
protein complex format 14 127 7.0
assay format 1 1 9.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine